Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piperacillin-tazobactam versus meropenem for AmpC-producing gram-negative bloodstream infection
ACTRN12614001211651Phase 4Completed
- Sponsor
- University of Queensland Centre for Clinical Research
- Start
- Jul 2015
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of piperacillin + tazobactam and meropenem in gram-negative bacteremia and Bacteremia, sponsored by University of Queensland Centre for Clinical Research. Primary endpoint: Primary composite endpoint. Started Jul 2015; status: completed.
02
Drugs
piperacillin + tazobactammeropenem
03
Conditions
gram-negative bacteremiaBacteremia
Beyond the preview
Go deeper on ACTRN12614001211651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614001211651.